propose to present the subject of recent advances in the treatment of pneumonia from the aspect with which I am most familiar, namely experiments in animals with chemotherapeutic substances.
good results have been confirmed by reports of small numbers of cases as well as of larger series from Africa [5] and America [6] . The results show clearly, in confirmation of experimental work, that the drug is not influenced by type and that provided the patient can live for twenty-four hours and can retain some 5 grm. of the drug, the chance of a successful issue is greatly increased this irrespective of the day of the disease on which treatment is begun, which is of course in strong contrast to the requirements of serum therapy. The report of Flippin and his colleagues [6] on a series of 100 cases (which had a fatality rate of 4%0 and which includes eight bacteriaemi ccases, with only one death) contains two significant statements, namely " Several patients who had received large doses of serum without apparent effect were given sulfapyridene and recovered " and " We instituted treatment in every case regardless of complications or the apparent terminal condition ". All this indicates that M & B 693 should be the first line of attack in a case of lobar pneumonia. Whether passive immunization with serum or active immunization with vaccine should be combined with the drug is a difficult question to decide. The combined methocl yields even better results in animals than does the drug alone, but in actual practice, by the time type has been determined or a vaccine made, the first twenty-four hours' dosage of M & B 693 will have given some indication as to its efficacy and the combined method need only be employed where necessary.
In general, the scheme of dosage suggested by Evans and Gaisfor(d [4] has been followed, and this scheme has given good results, namely 4 to 5 grm. in the first twenty-four hours, followed by 3 grm. daily up to a total dosage of 25 grm. There have as yet been no extensive studies to show what blood concentration such a course induces, but it has been established that the drug, owing to its insolubility, is not regularly absorbed in different individuals, that in some individuals just as good a result is obtained with a blood concentration of free drug from 1 to 3 mgm.0 as trom 10 to 18 mgm.0 %. This suggests that in certain individuals a lower dosage than 25 grm. may be used, and indicates that estimations of blood concentration will probably be an essential part of control in treatment. Flippin and his colleagues found that cases treated late in the disease, from the fifth day onwards, required no more than 15 grm. to bring about a crisis and effect cure.
In England it is difficult to obtain sufficient clinical material in one centre for a properly controlled investigation. But where such material is available I would press for the performance of complete laboratory control and investigation. It would be important to determine the fatality rate in bacterieemic cases, because bacteriaemia influences prognosis more than type and provides the best material for assessment. It would be important to do daily controls on blood concentration, first to get more information on minimal effective blood concentration and second to determine whether failures were due to poor absorption of the drug rather than to resistant and insensitive strains; the question of insensitivity would necessitate in vitro and in vivo tests on the strains isolated from cases that did not respond to treatment. It is well known that the drug in the blood exists partly as the active unchanged form and partly as the inactive acetylated form; the proportion in different individuals varies greatly. The significance of this individual reaction has not yet been assessed, but those who acetylate the drug readily may well be those who are resistant to treatment.
Evans and Gaisford have emphasized the importance of not stopping drug treatment as soon as a critical fall in temperature occurs ; rather must one continue with the course for about five days. The same feature is clearly shown by all animal experiments, namely, that abandonment of the drug before a period of at least four days is always associated with an exacerbation, which, in animals, is afterwards difficult to control.
Other problems of dose have also been investigated in animals. In order to obtain consistent cure in mice inoculated intraperitoneally with 10,000 lethal doses of living pneumococci, it is necessary to give three doses of 30 to 40 mgm. in the first twentyfour hours, followed by one dose of 40 mgm. daily for several days. If the dose used throughout is 20 mgm. instead of 40 mgm. the mortality is quite high. Estimations of the concentration of the drug in the blood show clearly that this mortality occurs not because 40 mgm. causes a higher concentration than does 20 mgm., but because on account of insolubility and slow absorption, 40 mgm. provides a depot which maintains the blood level at a reasonable point throughout a whole twenty-four hours. With 20-mgm. doses the blood level at the end of twenty-four hours is below an effective level. One can achieve a high proportion of cures in mice with doses as low as 2 mgm. provided the drug is administered four-hourly, night and day (Table I) . High doses of the drug are not, therefore, necessary to effect cure and increasing the dose beyond a certain point does not necessarily increase the blood concentration; the increase in dose merely maintains the blood level for a longer time. I shall comment again on this important fact because it implies that a sustained minimal blood concentration is of more importance than obtaining high concentrations.
In vitro experiments [3] clearly demonstrate that there is a quantitative relationship between drug concentration and the number of bacteria that can be destroyed. Thus, in vitro, a concentration of 16 mgm.00 will destroy 15,000 bacteria, whilst a concentration of 4 mgm.0 will destroy something of the order of 10 bacteria. But the fallacy of applying this principle to clinical medicine, by which I mean the giving of small doseto relatively mild infections and large doses to desperate infections, is shown clearly by in vivo animal experiment. With an in vivo experiment it is necessary to give almost as much drug to cure an inoculum of 10 lethal doses as it is to cure one of 10,000 lethal doses (Table II) . It is inconceivable that in human medicine there should exist clinical states which are caused by organisms numbering mere tens; one would always anticipate thousands or millions. 
4-0
I make this point because of the tendency, which exists in the profession, to use small doses in relatively mild infections or to give only a few doses. The basic indications for the use of this drug are clear, namely the occurrence of definite coccal infection; it is not a specific for every fever of unknown origin, and so far as I am aware it has no action in influenza unless there is secondary coccal infection. When the drug is used it should be used in full doses and for the full ordinary course.
The disadvantage of M & B 693 lies not in the rare serious complications which are common to all the sulphonamide group, namely, grave blood changes, and these must be relatively rare considering the pounds if not tons of the drug that have been Proceedings of the Royal ASociety of Medicine 40 used and abused in the past six months. The main disadvantage is that in some 30% of ill persons it acts as a gastric irritant causing vomiting, which is sometimes alarming. Often the vomiting subsides within twenty-four hours and the drug can then be continued, while various methods of administration, e.g. powdering, suspending in milk, fruit juice, or administering in smaller doses at more frequent intervals, can be used to tide over the initial ill phases. On account of this disadvantage of gastric irritation, search has naturally been made for a soluble preparation suitable for parentera] use, and considerable attention has been paid to the very soluble sodium salt, which has been carefully studied from the laboratory aspect before being released for the clinical trial which it is now undergoing. The laboratory studies emphasize certain principles which must be borne in mind when using this preparation in the human subject. This sodium salt of 2-sulphanilyl-aminopyridene is highly soluble; a 33% solution is readily prepared so that an ampoule of 3 c.c. contains 1 grmi; it has the disadvantage of having a pH of about 11, but when suitably diluted can be given even by the intravenous route; it is also, when diluted to about 2%, suitable for rectal administration and is fairly quickly absorbed. Because of its solubility it is also rapidly excreted. The maintenance of a constant effective blood concentration must involve multiple injections by night as well as by day. The history of the laboratory assessment of this drug will make this point clear. For some years I have been assessing the activity of new synthetic compounds by a routine method which has in the main given very satisfactory results. It involves the administration of the test drug at the time of inoculation, about seven hours after inoculation and then again once a day for several days. When sodium 2-sulphanilyl-aminopyridene was administered in this way, in the maximum tolerated doses, its activity was, relative to the insoluble parent substance, very small. The reason for this was soon clear when it was found that within a few hours of administration there was no drug at all in the blood-stream; it had all been excreted. Further investigations showed that after administration of the drug a high blood concentration, even a dangerously high one, was rapidly attained. Acting on these facts it was decided to re-assess the drug in small doses given at intervals of four hours, night and day-a laborious process-but one which demonstrated clearly the efficacy of this substance if properly used (Table III).   TABLE III Clearly the optimum dose, the spacing of doses, and the administration of this soluble drug to the human subject will require to be worked out carefully. One would anticipate that multiple injections of small amounts will be necessary. One might I .
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A ---9 -forecast that the main use of this drug will be to tide over the first twenty-four hours, after which the effect, if any, should be followed by oral administration of M & B 693, in order to maintain a proper blood concentration for the requisite time. It is important to note that once a critical fall in temperature has been attained the occurrence of vomiting with the oral compound is much less frequent. It seems unlikely that the soluble salt will entirely replace the ordinary M & B 693. In conclusion I shall summarize what, from the experimental aspect, appear to me to be important principles for the use of this powerful antipneumococcal and indeed antistreptococcal and even antistaphylococcal remedy. They are as follows:
(1) A good result is to be anticipated more in acute infections than in chronic.
(2) The maintenance of a steady, safe, and effective blood concentration, is more important than the attainment of high levels, while levels which fluctuate below minimal effective concentration are liable to be inefficient.
(3) Minor coccal infections require the same dosage for cure as do heavier infections. If, therefore, the drug is to be used, it should be used in full dose.
(4) Soluble preparations, and this applies to all soluble sulphonamide derivatives, are quickly absorbed and excreted. The maintenance of an adequate blood level with a soluble preparation requires to be carefully controlled. aphorism of Hippocrates is more fully true than of pneumonia. Experience is fallacious and judgment most certainly very difficult.
William Withering, at the outset of his original discourse on digitalis, remarked how much more easily one could write of a disease than of a remedy, and anyone who has tried to establish the facts of treatment, even in a clear-cut and common disease like pneumonia, will agree.
My contribution to this subject must concern itself with the serum treatment of the disease, much of which has already appeared in print from time to time during this past five years. The final figures, opinions, and results have slowly evolved over that period.
The importance of uniformity in any large series of cases can hardly be overestimated; the whole of the cases reported now have been derived from the working community of the city of Salford. They have all been treated in two special urgency wards of the Municipal Hospital, to which patients outside the city are not admitted. The whole work has been done by three colleagues working in happy combination, the Resident Medical Officer, the Assistant Pathologist, and the Visiting Physician. The cases have been received from the outside practitioners and the proportion of eases admitted before the end of the third day of disease would argue a high grade of efficiency.
The cases studied have been strictly limited to the age-group 16 to 60, and outside this limit in either direction we record nothing of pneumonia cases in this hospital.
Much effort has been expended in making the diagnosis of the disease as accurate as possible, both as regards the disease itself and as regards the causative organism. If the diagnosis be in doubt then the results of treatment are in still greater doubt. The precautions taken have been: careful clinical history; repeated examination by at least two observers; X-ray of the chest; bacteriological examination of both blood and sputum; typing of the organism; review of the whole case when terminated; post-mortem examination whenever possible. Records are maintained week by week and are not allowed to accumulate, with consequent gaps in the available information.
The general treatment of the patients has been uniform throughout; oxygen when required has been given by nasal catheter and a Wolff bottle. For sedatives medinal, paraldehyde, and morphia have been used as required. Ample glucose in a fluid diet has been pressed upon the patient and a very liberal supply of fresh air in the wards has always been maintained.
Serum has been administered in large doses by the intravenous route to all patients who (a) were admitted before the end of the third day of the disease and who (b) showed the presence of pneumococcus types I or II. So far all the serum used has been British. Unless the serum treatment could be started before the end of the third day of the disease, it was never used. This entailed a complete clinical and bacteriological diagnosis within the time limit set.
To form a control series, those cases admitted after the end of the third day of disease have been used; and this has caused considerable misgiving to the minds of the statisticians. The average duration of the disease on admission to hospital of the serum-treated group is two to three days, while that of the non-serum-treated group is four to nine days. It therefore remains to estimate the life-saving value of two and a half extra days in hospital. Had a true alternate case control been used in this work these objections had not been present, but the number of cases treated would have been halved and even now, after seven years of work, the numbers are too small for real significance. The important part played by age in the outcome of pneumonia is so widely recognized that any omission of this factor makes an opinion upon results almost impossible.
I regret that these tables cannot be read direct because of various disturbing factors which call for some comment. The factor of age is all too clear for those of us over the 40 mark, but what may be the factor which allows so large a proportion of those under 40 to reach hospital before the end of the third day of disease and yet makes so large a number of those over 40 to arrive after the third day?
To prove that this is not a selection within the hospital administration, the times of admission of the higher type cases have been worked out and reveal the same fact. How far would physicians of experience agree with me that the early diagnosis of pneumonia is very much easier in patients under 40 than in those over that age? There are obviously many added factors arising at an age nearer to 60 than arise at 25. A review of theMinistry of Health Reports and the relation of notified pneumonias to deaths from that cause serves to emphasize the importance of this subject, and these are the only really large figures available in this country.
The introduction about a year ago of diagnostic sera for the higher types of pneumococcus presented an opportunity for the further study of that mixed bag formerly referred to as group IV. It also involved pathologists in a great deal of extra work. So far we have made butlittle progress. Out of 38 cases investigated 12 failed to type at all, and of the remaining 26 we found 17 to fall within the types IV to VIII.
At the moment it appears true that we are unaware of the relative frequency of any of these higher types in this country and consequently we are unaware of the clinical course they are likely to run, and a great deal of laborious worklies ahead to make the necessary clinical and pathological observations. The outstanding lethal effect of type III pneumonia leaves one wondering whether another equally lethal type may yet be lurking about. At the same time as higher typing sera became available for clinical use M & B 693 was also introduced, together with experimental evidence, and some clinical evidence soon arrived to show that the drug was probably capable of modifying the course of lobar pneumonia in at least some cases. The mere clinical diagnosis of the disease is quite capable of offering very great difficulty, but in the future this will be very greatly increased when the drug has been given early in the disease. In fact it may well prove difficult or even impossible to determine how far the drug has been active in aborting a true pneumonia; and how far it has been given, and results claimed, when the diagnosis had not been adequately established.
So far the drug has been used in our service and in the manner prescribed in 34 cases with three deaths and severe vomiting in 13 instances. It has been given only in the types I and II cases admitted after the end of the third day and in type III. Of its success or failure it is impossible to speak, but one point is of great interest: in the past eight years we have identified only nine cases of type III pneumonia, all of whom have died. Recently three cases have occurred and have been treated with the drug, and all three have recovered; the first recoveries from this type of pneumonia which I have ever seen. It is true that two out of the three cases were under 30, and that during last week another case of type III arose which unfortunately died in spite of the drug, but the primary fact remains.
It is hoped that the reason for limiting the use of the drug in the manner indicated is clear. Unless it is possible to study the higher-type pneumonias in their course undey expectant treatment, it will remain impossible to judge the effect of any treatment; in fact we shall permanently lack controls. The combined higher types usually constituted about 25%O of the total pneumonias, but in U.S.A. only V, VII, and VIII are responsible for more than 5% of cases, so that it will be necessary to classify and study 2,000 cases of pneumonia before the clinical course of any member of the higher group can be established in 100 cases, and this sounds very like crying for the moon in that it has occupied eight years to collect 1,200 cases.
It has been shown that an attack of pneumonia followed by recovery usually leaves the patient a carrier for about a month; recovery of the type organism becoming more and more difficult with the lapse of time. I have very little evidence which makes me anxious to know whether treatment with M & B 693 has any effect upon the recovery of the organism from the sputum. Any information on this point would be most welcome, for it is obvious that if the pneumococcus is caused to disappear, bacteriological diagnosis becomes impossible thereafter, and we may find ourselves anxious to withdraw that old and hitherto true dictum-" happy is the physician who sees the patient last ".
The criticisms which have appeared in the American pr3ss and which were reviewed in the last number of the Lancet (1939 (i), 703) must have received considerable attention, and it may be well to remember the many years of work and labouir contributed by our cousins and the high grade of efficiency to which they have attained in State serum treatment. The type of statistical criticism to which serum work has been subjected will call for a quite similar investigation of results attained by this drug, and it is for this that the American workers are asking in all fairness. PNEUMAONIA 
